Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia.

about

Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia.

Item

http://www.wikidata.org/entity/Q55205941

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Inotuzumab ozogamicin in the t ...... B cell lymphoblastic leukemia.

@en

Inotuzumab ozogamicin in the t ...... B cell lymphoblastic leukemia.

@nl

type

Item

label

Inotuzumab ozogamicin in the t ...... B cell lymphoblastic leukemia.

@en

Inotuzumab ozogamicin in the t ...... B cell lymphoblastic leukemia.

@nl

prefLabel

Inotuzumab ozogamicin in the t ...... B cell lymphoblastic leukemia.

@en

Inotuzumab ozogamicin in the t ...... B cell lymphoblastic leukemia.

@nl

P1476

Inotuzumab ozogamicin in the t ...... B cell lymphoblastic leukemia.

@en

P2093

Amer M Zeidan

http://www.w3.org/2001/XMLSchema#string

Maximilian Stahl

http://www.w3.org/2001/XMLSchema#string

Michelle Nadeau

http://www.w3.org/2001/XMLSchema#string

Natalie Uy

http://www.w3.org/2001/XMLSchema#string

P2860

Cleavage behavior of calicheamicin gamma 1 and calicheamicin T

Monoclonal antibodies in acute lymphoblastic leukemia

Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study.

Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma.

Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies.

Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia.

Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies.

Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial.

Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin.

Immunotherapy approaches to treat adult acute lymphoblastic leukemia.

P304

67-74

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/JBM.S136575

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-04-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29713210

http://www.w3.org/2001/XMLSchema#string

P921

leukemia

P932

5908210

http://www.w3.org/2001/XMLSchema#string